CNO Financial Group, Inc. (CNO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with significant growth in key insurance segments, robust ROE, and disciplined capital management. The Q&A reveals management's confidence in sustaining growth and improving ROE, despite some market uncertainties. The company's strategic focus on demographic trends and business growth supports a positive outlook. However, the lack of precise guidance on future ROE improvements and mortality trends adds some uncertainty. Given the company's market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
Key Financial Performance
Operating earnings per diluted share $1.05, up 33% year-over-year (42% excluding significant items). The increase reflects continued profitable sales growth, strength in underwriting results, growth in net investment income driven by growth in assets, together with higher yields, and ongoing discipline in expense and capital management.
Total new annualized premiums Up 11% year-over-year. Growth attributed to strong sales across both divisions, exclusive middle market focus, and captive agent distribution model.
Book value per diluted share (excluding AOCI) $38.98, up 5% year-over-year. Growth reflects strong capital position and shareholder returns.
Life and Health NAP (Consumer division) Up 9% year-over-year. Growth driven by consistent execution and focus on the middle-income market.
Total Health NAP Up 20% year-over-year. Growth attributed to strong performance in supplemental health and Medicare business.
Medicare Supplement NAP Up 53% year-over-year. Growth reflects shift in consumer preferences away from Medicare Advantage and toward Medicare Supplement.
Annuity collected premiums $434 million, down 2% year-over-year. Decline attributed to a strong comparable period.
Account values Up 7% year-over-year. Growth reflects sustained brokerage and advisory growth.
Client assets Up 27% year-over-year to a new record. Growth driven by brokerage and advisory growth.
Producing agent count Up 3% year-over-year. Growth reflects strong agent productivity and retention.
Registered agent count Up 7% year-over-year. Growth reflects successful agent recruiting efforts.
Life and Health NAP (Worksite division) Up 22% year-over-year. Growth driven by focus on small to midsized businesses and associations, geographic expansion, and new client relationships.
Life insurance (Worksite division) Up 56% year-over-year. Growth attributed to new client relationships.
Hospital indemnity insurance Up 121% year-over-year. Growth attributed to focus on small to midsized businesses and associations.
Accident insurance Up 18% year-over-year. Growth attributed to focus on small to midsized businesses and associations.
Net investment income Up 6% year-over-year. Growth driven by growth in net insurance liabilities and related assets, and improvement in book yields supported by new money rates above 6%.
Operating return on equity (trailing 12-month basis) 13.1% (12.2% excluding significant items). Growth reflects profitable sales growth and disciplined expense and capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Medicare Supplement NAP: Up 53%, reflecting a shift in consumer preferences away from Medicare Advantage and towards Medicare Supplement.
Life and Health NAP: Up 9% for the quarter, with a 9% 3-year compound annual growth rate.
Supplemental Health: Up 10%.
Medicare Policies: Total Medicare policies sold were up 24%.
Life Insurance: Up 56% in the Worksite division.
Hospital Indemnity Insurance: Up 121% in the Worksite division.
Accident Insurance: Up 18% in the Worksite division.
Geographic Expansion: Contributed to a 65% increase in NAP from new clients in the Worksite division.
Medicare Market: Industry-wide Medicare Advantage enrollment growth slowed to 3%, the weakest pace in 20 years, while CNO capitalized on the shift towards Medicare Supplement.
Agent Productivity and Retention: Strong agent productivity and retention fueled sustained sales momentum, with producing agent count up 3% and registered agent count up 7%.
Technology and AI Investments: AI is being used in the Colonial Penn call center to improve customer wait times and sales conversions. Multiple initiatives are underway to advance technology and AI.
Expense Management: Operating expense ratio was 18.9%, reflecting disciplined expense management.
Focus on Middle-Income Market: Continued focus on middle-income households to drive financial security and protection.
Diversified Product Portfolio: Maintained a diversified product portfolio to ensure stable and growing margins over time.
Capital Deployment: $60 million of excess capital deployed on share repurchases, contributing to a 7% reduction in weighted average diluted shares outstanding.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Supplement Claims Experience: The Medicare Supplement faced modestly adverse claims experience, which could impact profitability. Rate increases are expected to address this issue over the course of 2026.
Macroeconomic Volatility: The company acknowledges a volatile macroeconomic environment, which could pose risks to financial performance and strategic execution.
Alternative Investment Income: Alternative investment income was slightly below expectations, which may affect overall investment income growth.
Medicare Advantage Market Disruption: Significant disruption in the Medicare Advantage market, including plan terminations and slowed enrollment growth, could impact the company's Medicare-related business.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Guidance Affirmation: The company is affirming its original guidance for 2026, citing a volatile macroeconomic environment and the fact that three quarters remain in the year. Projections will be refined later in the year.
3-Year Operating Return on Equity (ROE) Target: The company has indicated that its recent ROE results make it likely to increase its 2027 ROE ambitions. However, updates to the 2027 ROE target will not be made until early next year.
Medicare Supplement Rate Increases: The company expects rate increases over the course of 2026 to address recent claims experience in the Medicare Supplement segment.
Capital Deployment: The company plans to continue a disciplined approach to expense and capital management, reinvesting in the business to support growth while generating free cash flow for dividends and share repurchases.
Investment Strategy: The company will maintain a disciplined investment posture, focusing on durable income generation and flexibility in a volatile market. New investments in Q1 2026 totaled $1.3 billion with an average duration of 5 years.
Technology and AI Initiatives: The company is advancing its technology and AI roadmap, with multiple initiatives underway to enhance efficiency, agent productivity, and customer experience. Examples include AI-driven improvements in call center operations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: The company returned $77 million to shareholders during the quarter, which includes dividends.
Share Repurchases: The company deployed $60 million of excess capital on share repurchases, contributing to a 7% reduction in weighted average diluted shares outstanding.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the pricing plans for the Med Supp business and the timing of premium increases?
A:Paul McDonough explained that rate increases were filed in two buckets for 2025: one with a January 1, 2026 effective date (10.5% requested, 10.2% approved) and another with a July 1, 2026 effective date (16.8% requested, 14.5% expected approval). These increases will earn in over time, with full quarterly impact evident by Q4 2026, improving benefit ratios depending on claims experience.
Q:Are the two Med Supp buckets similarly sized?
A:Paul McDonough stated that the closed block is about two-thirds the size, while the open block is roughly one-third.
Q:What is the outlook for the Consumer segment, particularly Health NAP, life, D2C, and annuities?
A:Gary Bhojwani noted strong demand for products like Health NAP, citing demographic trends and the absence of alternatives. He attributed minor fluctuations in annuities to quarter-to-quarter variances and emphasized focusing on 1- and 3-year trends rather than short-term fluctuations.
Q:Are the favorable expenses this quarter timing-related or indicative of a trend?
A:Paul McDonough explained that expenses typically vary across quarters, with higher expenses expected in Q1. However, this year’s expenses did not follow that pattern. Full-year expenses are expected to align with original plans, with potential favorability due to business growth.
Q:What is the perspective on the current credit markets and opportunities for deploying new money?
A:Eric Johnson highlighted stable credit markets with limited opportunities for high returns at lower risk. The company maintained a conservative approach, focusing on shorter durations and waiting for better entry points for strategic changes.
Q:What are the drivers of the recent ROE outperformance, and are they sustainable?
A:Paul McDonough attributed ROE improvement to actions across the business value chain, including growth, expense management, investment portfolio returns, and capital optimization. These factors are expected to continue driving ROE improvement.
Q:What are the expectations for long-term care experience and margins?
A:Paul McDonough stated that long-term care continues to perform well, with stable and favorable claims experience. Margins around 50% are considered sustainable, and assumptions will be revisited in Q3.
Q:Are there any offsets or normalizations to consider for the ROE trajectory?
A:Paul McDonough noted that while operating earnings and capital efficiency will drive ROE growth, non-operating income volatility could create short-term noise. Gary Bhojwani emphasized that the 12% ROE target is a waypoint, with plans to exceed it over time.
Q:What was the impact of lower equity markets on the RBC ratio, and is there a recovery?
A:Paul McDonough explained that the S&P 500’s 5% decline in Q1 impacted reserves and RBC ratio. However, equity market recovery in Q2 is expected to neutralize this impact over the year.
Q:What is the outlook for the FABN market this year?
A:Eric Johnson noted that unfavorable spreads in Q1 made issuing FABNs less attractive. However, conditions are improving, and the company will reassess in June. There is no pressure to issue unless conditions align with their risk and quality standards.
Q:What are the mortality expectations for the year?
A:Paul McDonough reported favorable mortality in the Trad life business within the normal range of expectations. Assumptions will be revisited in Q3.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timeline or magnitude of ROE improvements beyond the 12% target, stating only that it is a waypoint and improvements will continue. Additionally, they did not provide precise expectations for mortality trends or long-term care margins beyond general favorable trends.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AEP industry
AI road
AI route
AOCI Slide
Advantage agent
Agent recruiting
Auvil VP
CNO ability
Colonial Penn
DC life
FHLB FABN
Group Results
Investor Relations
Life Health
Worksite
agent distribution
balance
capital Slide
capital position
career
carrier
claim experience
compound rate
customer
distribution model
division start
enrollment period
environment
expense capital
flexibility
focus
household
month
opening
risk capital
sale agent
sale compound
share item
CNO Transcript
CNO Financial Group, Inc. (CNO) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call indicates strong financial performance with significant growth in key insurance segments, robust ROE, and disciplined capital management. The Q&A reveals management's confidence in sustaining growth and improving ROE, despite some market uncertainties. The company's strategic focus on demographic trends and business growth supports a positive outlook. However, the lack of precise guidance on future ROE improvements and mortality trends adds some uncertainty. Given the company's market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
CNO Financial Group, Inc. (CNO) Q4 2025 Earnings Call Transcript
Positive2-6
The earnings call reflects a positive outlook with strong financial performance, improved ROE targets, and increased shareholder returns. Despite some challenges in discretionary purchases and Medicare Advantage, the company expects growth in Medicare Supplement sales, aligning with demographic trends. The Q&A session revealed confidence in hitting targets and maintaining regulatory relationships, although there were some vague responses. The market cap suggests moderate sensitivity to positive news, leading to an expected stock price increase of 2% to 8% over the next two weeks.
CNO Financial Group, Inc. (CNO) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary and Q&A reveal a positive outlook with strong revenue growth across multiple product lines, improved expense ratio guidance, and strategic capital deployment. Despite some unclear management responses, the strong D2C sales and partnerships, along with optimistic guidance, outweigh the concerns. The company's focus on shareholder returns through share repurchases and investments in growth is likely to drive a positive stock price movement. Given the market cap of $2.98 billion, a positive reaction of 2% to 8% is anticipated over the next two weeks.
CNO Financial Group, Inc. (CNO) Q2 2025 Earnings Call Transcript
Positive7-29
The earnings call summary and Q&A indicate strong financial performance, with growth across divisions, solid investment income, and a positive outlook on direct-to-consumer sales. While there were no specific new partnership announcements, the reaffirmation of 2025 guidance and stable financial health are positives. The Q&A addressed potential concerns, showing confidence in sustaining growth and managing competition. The market cap suggests moderate sensitivity, leading to a positive short-term stock price reaction.
CNO Slides
CNO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
